A new edition of the Handbook has always seen important developments, and this edition is no exception. Not only has the entire volume been reviewed and updated, significant new content has been added.
Special offer price - available now.
A new edition of the Handbook has always seen important developments, and this edition is no exception. Not only has the entire volume been reviewed and updated, significant new content has been added.
This includes 40 new monographs – bringing the total to 380 – written by a team of over 150 of the world’s leading pharmaceutical scientists. Monographs are extensively illustrated with images(SEMs), chemical structures, spectra and tables to support easy interpretation of the text.
With every new edition, the Handbook has increased in breadth and depth, making it increasingly valuable to drug formulators, manufacturers, regulatory and legal bodies, and establishing it as the go-to reference work on excipients. Pharmacists and chemists – in practice, in training and at work in a wide variety of industries – rely upon its authority and trust its content.
No reference work surpasses the Handbook of Pharmaceutical Excipients in the international recognition of the authority of its content and the respect for its editorial board and contributors.
“…the publisher and editors have once again published an excellent book which has utility for all of us involved in the pharmaceutical industry.” .
The British Toxicology Society
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.